Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Valent

Showing results (491-500 of 662) with videos related to

Pageof 67
Sort By:
Blood|January 9, 2008
The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophilsMichael Kneidinger, Uwe Schmidt, Uwe Rix, et al.
Leukemia|May 7, 2026
CAR T-cells targeting CD117 effectively eliminate mast cells in preclinical models of advanced systemic mastocytosisAnne Kaiser, Veronika Lysenko, Renier Myburgh, et al.
Leukemia|March 31, 2021
Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemiaGregor Eisenwort, Irina Sadovnik, Alexandra Keller, et al.
Blood|January 13, 2019
CDK6 coordinates <i>JAK2</i> <sup><i>V617F</i></sup> mutant MPN via NF-κB and apoptotic networksIris Z Uras, Barbara Maurer, Harini Nivarthi, et al.
Blood|August 30, 2007
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patientsDetlef Haase, Ulrich Germing, Julie Schanz, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 24, 2005
Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cellsMatthias Mayerhofer, Karl J Aichberger, Stefan Florian, et al.
Blood|November 21, 2007
Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinibMatthias Mayerhofer, Karoline V Gleixner, Julia Mayerhofer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous LeukemiaSieghart Sopper, Satu Mustjoki, Deborah White, et al.
Blood|February 12, 2016
Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinasesYashodhara Dasgupta, Mateusz Koptyra, Grazyna Hoser, et al.
Blood Advances|October 21, 2020
Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CMLHarald Herrmann, Irina Sadovnik, Gregor Eisenwort, et al.
Pageof 67

Showing results (491-500 of 662) with videos related to

Sort By:
Pageof 67
Blood|January 9, 2008
The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophilsMichael Kneidinger, Uwe Schmidt, Uwe Rix, et al.
Leukemia|May 7, 2026
CAR T-cells targeting CD117 effectively eliminate mast cells in preclinical models of advanced systemic mastocytosisAnne Kaiser, Veronika Lysenko, Renier Myburgh, et al.
Leukemia|March 31, 2021
Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemiaGregor Eisenwort, Irina Sadovnik, Alexandra Keller, et al.
Blood|January 13, 2019
CDK6 coordinates <i>JAK2</i> <sup><i>V617F</i></sup> mutant MPN via NF-κB and apoptotic networksIris Z Uras, Barbara Maurer, Harini Nivarthi, et al.
Blood|August 30, 2007
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patientsDetlef Haase, Ulrich Germing, Julie Schanz, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 24, 2005
Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cellsMatthias Mayerhofer, Karl J Aichberger, Stefan Florian, et al.
Blood|November 21, 2007
Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinibMatthias Mayerhofer, Karoline V Gleixner, Julia Mayerhofer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous LeukemiaSieghart Sopper, Satu Mustjoki, Deborah White, et al.
Blood|February 12, 2016
Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinasesYashodhara Dasgupta, Mateusz Koptyra, Grazyna Hoser, et al.
Blood Advances|October 21, 2020
Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CMLHarald Herrmann, Irina Sadovnik, Gregor Eisenwort, et al.
Pageof 67